Treatment of Deep Vein Thrombosis (DVT)

Immediate Anticoagulation Strategy

The American College of Chest Physicians recommends starting a direct oral anticoagulant (DOAC) immediately upon diagnosis of DVT, specifically apixaban, rivaroxaban, dabigatran, or edoxaban, as first-line therapy for most patients with acute DVT 1
Begin treatment immediately upon clinical suspicion of DVT, even before confirmatory imaging if suspicion is high, to reduce the risk of pulmonary embolism 2, 3
DOACs are strongly preferred over warfarin for the treatment phase due to superior safety profile, no monitoring requirements, and at least equivalent efficacy 1, 4

In patients with DVT and active cancer, use an oral factor Xa inhibitor (apixaban, edoxaban, or rivaroxaban) over low-molecular-weight heparin (LMWH) as first-line therapy 1, 4
Extended anticoagulation (no scheduled stop date) is recommended for as long as cancer remains active 1, 4

Start parenteral anticoagulation (LMWH, fondaparinux, or unfractionated heparin) on day 1 simultaneously with warfarin 6, 4
Continue parenteral therapy for minimum 5 days AND until INR ≥2.0 for at least 24 hours 6, 4
Target INR range is 2.0-3.0 (target 2.5) 4

For provoked DVT, treat for exactly 3 months, then stop 1, 4
For unprovoked DVT or persistent risk factor, offer extended anticoagulation (no scheduled stop date) with a DOAC if bleeding risk is low to moderate 1, 4

Home-based outpatient treatment is recommended over hospitalization for patients with adequate home circumstances, family support, phone access, and ability to return quickly if needed 6, 7, 2

Do NOT use IVC filters in patients who can receive anticoagulation 6, 4, 7
Anticoagulation alone is preferred over catheter-directed thrombolysis for most DVT patients 6, 7

In confirmed antiphospholipid syndrome, suggest adjusted-dose warfarin (target INR 2.5) over DOACs during treatment phase 1, 4
For upper extremity DVT, recommend acute treatment with parenteral anticoagulation (LMWH or fondaparinux preferred) 5
For superficial vein thrombosis (≥5 cm), suggest fondaparinux 2.5 mg daily for 45 days over no anticoagulation 1, 7, 2